ALK and non-small cell lung carcinoma: Therefore, to further improve the clinical outcomes for ALK-positive NSCLC patients, it is necessary to comprehensively understand the underlying mechanisms of ALK-TKI resistance and develop novel therapeutic strategies to overcome it.